Last reviewed · How we verify

NCT05692648

Effect of Repositioning Frequency Neonates Receiving Phototherapy

Completed NA Last updated 20 January 2023
What this trial tests

NA trial testing Supine position group in Bilirubinemia in 60 participants. Completed in 30 September 2020.

Timeline
1 February 2020
Primary endpoint
30 August 2020
30 September 2020

Quick facts

Lead sponsorSelcuk University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment60
Start date1 February 2020
Primary completion30 August 2020
Estimated completion30 September 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Selcuk University

Who can join

Adults 35 Weeks to 42 Weeks, any sex, with Bilirubinemia or Newborn Jaundice. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: The present study was conducted to determine the effect of repositioning frequency during phototherapy on bilirubin level and neonates comfort. Design and methods: This was a single-centered, single-blind, 3-arm, pretest-posttest parallel-group randomized controlled trial conducted in a neonatal intensive care unit. Participants were randomly assigned to one of three groups: Supine position group (n = 20), hourly position change group (n = 20), and control group (n = 20). The bilirubin level and comfort levels of the neonates were evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Selcuk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05692648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing